Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bone scan boost: could Whole-Body SPECT sharpen radiation targeting for metastatic prostate cancer?

NCT ID NCT06439784

Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial explores whether a whole-body bone scan (SPECT/CT) taken in the treatment position can help doctors plan stereotactic radiotherapy more precisely for prostate cancer that has spread to the bones. Thirty patients will receive the scan in addition to standard imaging, and researchers will compare radiation plans created with and without the SPECT images. The goal is to see if the SPECT-based plans are equivalent or better, potentially allowing for more accurate targeting of tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
whole-body SPECT/CT imaging using VERITON-CT CZT camera
What this could lead to
If SPECT/CT proves equivalent or superior to standard imaging, it could enable more precise radiotherapy planning and potentially better outcomes for prostate cancer patients with bone metastases.
What could go wrong
This is a small, early feasibility study with only 30 participants. The imaging technique may not translate into meaningful clinical benefits, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, * Good general health WHO ≤ 1 * Informed and signed consent prior to any specific study procedure. * Patient affiliated to the social security system * Bone metastases from prostate cancer * Indication for bone stereotactic radiotherapy Exclusion Criteria: * Presence of active cancer in the previous three years * Protected adults (under guardianship or curatorship) * Unable to undergo medical monitoring for geographical, social or psychological reasons * Unable to decubitus (orthopnea, etc.), * Hypersensitivity to HDP or to one of the excipients of the radiopharmaceutical. * History of radiotherapy of the volume to be treated by stereotaxy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer with bone metastases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, 76038, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.